WO2002075302A8 - Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal - Google Patents

Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal

Info

Publication number
WO2002075302A8
WO2002075302A8 PCT/US2002/007555 US0207555W WO02075302A8 WO 2002075302 A8 WO2002075302 A8 WO 2002075302A8 US 0207555 W US0207555 W US 0207555W WO 02075302 A8 WO02075302 A8 WO 02075302A8
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cardiopathology
types
offspring
clinically recognized
Prior art date
Application number
PCT/US2002/007555
Other languages
French (fr)
Other versions
WO2002075302A1 (en
Inventor
Yong-Fu Xiao
James P Morgan
Original Assignee
Yong-Fu Xiao
James P Morgan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yong-Fu Xiao, James P Morgan filed Critical Yong-Fu Xiao
Priority to EP02753613A priority Critical patent/EP1379869A4/en
Priority to CA002441289A priority patent/CA2441289A1/en
Priority to JP2002573666A priority patent/JP2004532202A/en
Publication of WO2002075302A1 publication Critical patent/WO2002075302A1/en
Priority to US10/438,574 priority patent/US20040071665A1/en
Publication of WO2002075302A8 publication Critical patent/WO2002075302A8/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0663Bone marrow mesenchymal stem cells (BM-MSC)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027New breeds of vertebrates
    • A01K67/0271Chimeric animals, e.g. comprising exogenous cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0606Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Abstract

The present invention provides therapeutic methods which employ one or more identifiable types of mammalian stem cells, and/or their progenitor progeny cells, and/or their lineage-committed descendant cells, and/or their partially-differentiated offspring cells - with or without completely differentiated cells to treat living mammalian subjects afflicted with a clinically recognized form of cardiopathology. The identifiable cell types include embryonic stem cells and their offspring cells; as well as the presently identified types of adult stem cells and their various offspring cells; and also include recently identified alternative cells types which have functional stem cell properties. Among the clinical forms of cardiopathology which can be efficaciously treated using the present therapeutic methods are myocardial infarction, myocarditis, heart failure, and cardiac dysrhythmia.
PCT/US2002/007555 2000-09-05 2002-03-14 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal WO2002075302A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02753613A EP1379869A4 (en) 2001-03-15 2002-03-14 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
CA002441289A CA2441289A1 (en) 2001-03-15 2002-03-14 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
JP2002573666A JP2004532202A (en) 2001-03-15 2002-03-14 Method of therapeutically treating a clinically recognized form of a cardiac condition in a living mammal
US10/438,574 US20040071665A1 (en) 2000-09-05 2003-05-15 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US27617501P 2001-03-15 2001-03-15
US27614801P 2001-03-15 2001-03-15
US27624701P 2001-03-15 2001-03-15
US27624301P 2001-03-15 2001-03-15
US27614701P 2001-03-15 2001-03-15
US27624501P 2001-03-15 2001-03-15
US27624601P 2001-03-15 2001-03-15
US27624401P 2001-03-15 2001-03-15
US60/276,244 2001-03-15
US60/276,245 2001-03-15
US60/276,243 2001-03-15
US60/276,147 2001-03-15
US60/276,148 2001-03-15
US60/276,246 2001-03-15
US60/276,175 2001-03-15
US60/276,247 2001-03-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/438,574 Continuation US20040071665A1 (en) 2000-09-05 2003-05-15 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal

Publications (2)

Publication Number Publication Date
WO2002075302A1 WO2002075302A1 (en) 2002-09-26
WO2002075302A8 true WO2002075302A8 (en) 2007-09-07

Family

ID=27575321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/007555 WO2002075302A1 (en) 2000-09-05 2002-03-14 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal

Country Status (4)

Country Link
EP (1) EP1379869A4 (en)
JP (1) JP2004532202A (en)
CA (1) CA2441289A1 (en)
WO (1) WO2002075302A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691216B2 (en) 2001-12-07 2014-04-08 Cytori Therapeutics, Inc. Methods of using regenerative cells to promote wound healing
US8883499B2 (en) 2001-12-07 2014-11-11 Cytori Therapeutics, Inc. Systems and methods for isolating and using clinically safe adipose derived regenerative cells
US9133431B2 (en) 2009-05-01 2015-09-15 Bimini Technologies Llc Systems, methods and compositions for optimizing tissue and cell enriched grafts
US9198937B2 (en) 2001-12-07 2015-12-01 Cytori Therapeutics, Inc. Adipose-derived regenerative cells for treating liver injury
US9463203B2 (en) 2001-12-07 2016-10-11 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of cartilage defects
US9480718B2 (en) 2001-12-07 2016-11-01 Cytori Therapeutics, Inc. Methods of using adipose-derived regenerative cells in the treatment of peripheral vascular disease and related disorders
US9486484B2 (en) 2008-08-19 2016-11-08 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008506416A (en) * 2004-07-19 2008-03-06 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク Analytical system for monitoring the effect of genetically modified cells on the functioning of syncytia
CA2609361C (en) * 2005-05-25 2017-11-14 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
EP2529235B1 (en) * 2010-01-29 2019-03-06 Metanomics GmbH Means and methods for diagnosing heart failure in a subject
JP5628131B2 (en) * 2011-10-19 2014-11-19 サイトリ セラピューティクス インコーポレイテッド Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
WO2014040759A1 (en) * 2012-09-12 2014-03-20 Roche Diagnostics Gmbh Identification of patients with abnormal fractional shortening
CA3153237A1 (en) * 2019-09-05 2021-03-11 Tohoku University Therapeutic agent for myocarditis
CN114176049B (en) * 2022-01-20 2023-01-31 河南农业大学 Method for simultaneously improving bee emergence rate and female worm number of indoor bred cotton bollworm tooth-lipped ichneumon fly

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US20020098167A1 (en) * 2000-07-31 2002-07-25 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
US20030031651A1 (en) * 2001-04-13 2003-02-13 Lee Ike W. Methods and reagents for cell transplantation
JP5479661B2 (en) * 2001-07-24 2014-04-23 イーエス・セル・インターナショナル・ピーティーイー・リミテッド Methods for inducing stem cell differentiation

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691216B2 (en) 2001-12-07 2014-04-08 Cytori Therapeutics, Inc. Methods of using regenerative cells to promote wound healing
US8883499B2 (en) 2001-12-07 2014-11-11 Cytori Therapeutics, Inc. Systems and methods for isolating and using clinically safe adipose derived regenerative cells
US9198937B2 (en) 2001-12-07 2015-12-01 Cytori Therapeutics, Inc. Adipose-derived regenerative cells for treating liver injury
US9463203B2 (en) 2001-12-07 2016-10-11 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of cartilage defects
US9480718B2 (en) 2001-12-07 2016-11-01 Cytori Therapeutics, Inc. Methods of using adipose-derived regenerative cells in the treatment of peripheral vascular disease and related disorders
US9492483B2 (en) 2001-12-07 2016-11-15 Cytori Therapeutics, Inc. Methods of using regenerative cells to treat a burn
US9504716B2 (en) 2001-12-07 2016-11-29 Cytori Therapeutics, Inc. Methods of using adipose derived regenerative cells to promote restoration of intevertebral disc
US9511094B2 (en) 2001-12-07 2016-12-06 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
US9511096B2 (en) 2001-12-07 2016-12-06 Cytori Therapeutics, Inc. Methods of using regenerative cells to treat an ischemic wound
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US9486484B2 (en) 2008-08-19 2016-11-08 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
US9133431B2 (en) 2009-05-01 2015-09-15 Bimini Technologies Llc Systems, methods and compositions for optimizing tissue and cell enriched grafts

Also Published As

Publication number Publication date
WO2002075302A1 (en) 2002-09-26
EP1379869A1 (en) 2004-01-14
CA2441289A1 (en) 2002-09-26
JP2004532202A (en) 2004-10-21
EP1379869A4 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
WO2002075302A8 (en) Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
Lieu et al. Mechanism-based facilitated maturation of human pluripotent stem cell–derived cardiomyocytes
JP5908582B2 (en) Method for treating mesenchymal stem cells and its application as a treatment for diseases related to oxidative stress
Jiang et al. Bone marrow mesenchymal stem cells can improve the motor function of a Huntington's disease rat model
WO2002064157A3 (en) Localized myocardial injection method for treating ischemic myocardium
WO2001038503A3 (en) Novel human protein kinases and protein kinase-like enzymes
DK1007631T4 (en) Cardiac muscle regeneration using mesenchymal stem cells
WO2005046570A3 (en) Human stem cell materials and methods
Jackson et al. Neurotrophin regulation of energy homeostasis in the central nervous system
Shihabuddin et al. Neural stem cell transplantation as a therapeutic approach for treating lysosomal storage diseases
Ryu et al. Brain transplantation of neural stem cells cotransduced with tyrosine hydroxylase and GTP cyclohydrolase 1 in Parkinsonian rats
KR20180091101A (en) Induced cardiac pacemaker from adult stem cells and furcine cells
Papadimas et al. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy
Bak et al. The role of heme oxygenase-related carbon monoxide and ventricular fibrillation in ischemic/reperfused hearts
WO2001021771A3 (en) Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
Jiaming et al. Comparing neuroprotective effects of CDNF-expressing bone marrow derived mesenchymal stem cells via differing routes of administration utilizing an in vivo model of Parkinson’s disease
DE60230774D1 (en) INSULATION OF NERVE STEM CELLS USING GANGLIOSIDES AND OTHER SURFACE MARKERS
DE602005017812D1 (en) MULTIPOTENTIAL BLOOD CELLS FROM THE NAIL CORD AND CELL TREATMENT AGENT THEREFORE FOR THE TREATMENT OF ISCHEMIC ILLNESS
BR9906926A (en) Compositions and methods for treating cells having double minute dna
Yi et al. Role of angiotensin II in aging
CN104548136B (en) A kind of piRNA medical composition and its uses
Kim et al. Changes of gene expression after bone marrow cell transfusion in rats with monocrotaline-induced pulmonary hypertension
Oki et al. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice
WO2005094267A3 (en) Methods for regulating differentiation of neural cells and uses thereof
MX2007015127A (en) Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10438574

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2441289

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002573666

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002306702

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002753613

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002753613

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002753613

Country of ref document: EP